Introduction to Zestril (Lisinopril)
Zestril, commonly known by its generic name lisinopril, is an angiotensin-converting enzyme (ACE) inhibitor. It is primarily prescribed to treat high blood pressure (hypertension), heart failure, and certain kidney conditions related to diabetes. Here, we will delve into the current clinical trials, market analysis, and future projections for this medication.
Clinical Trials and Research
Ongoing and Upcoming Studies
One of the notable ongoing studies involving Zestril is the OptiZest study, a collaboration between Closed Loop Medicine and Pharmanovia. This study aims to investigate whether a personalised dose of Zestril (lisinopril) can improve blood pressure control in patients with hypertension. The study utilizes Closed Loop’s proprietary Software-as-a-Medical Device (SaMD) dose optimisation technology to tailor the medication dosage to individual patient needs, potentially enhancing blood pressure control and minimizing side effects[4].
Previous Trial Outcomes
Recent trials, such as the PERSONAL-COVIDBP clinical trial, have shown promising results for personalised hypertension management using technologies similar to those employed in the OptiZest study. These trials have demonstrated the ability to control blood pressure effectively while minimizing adverse reactions and supporting medication adherence[4].
Market Analysis
Current Market Size and Growth
The global lisinopril market has been growing steadily. In 2023, the market size was approximately $1.66 billion, and it is expected to grow to $1.76 billion in 2024 at a compound annual growth rate (CAGR) of 6.0%[2].
By 2031, the market is projected to reach $317.15 million, with a CAGR of 4.30% during the forecast period. The dominant segment driving this growth is the treatment of hypertension, due to the widespread use of lisinopril in managing this condition[3].
Regional Market Performance
North America was the largest region in the lisinopril market in 2023, but the Asia-Pacific region is expected to be the fastest-growing during the forecast period. Other significant regions include Western Europe, Eastern Europe, South America, the Middle East, and Africa[2].
Market Segmentation
The lisinopril market is segmented based on several factors:
- Disease: Hypertension, heart failure, heart attack, strokes, diabetic kidney disease, and others.
- Dosage: Tablet, liquid, and others.
- Dosage Strength: Various strengths such as 10mg/12.5mg, 20mg/12.5mg, and 20mg/25mg.
- Brand: Zestril, Prinivil, Zestoretic, and others.
- Population Type: Children and adults.
- End-Users: Hospitals, specialty clinics, home healthcare, and others.
- Distribution Channel: Direct tender, hospital pharmacy, retail pharmacy, online pharmacy, and others[3].
Market Projections
Future Growth and Trends
The lisinopril market is expected to continue its growth trajectory driven by several key factors:
- Increasing Prevalence of Hypertension and Cardiovascular Diseases: The rising prevalence of these conditions globally is a significant driver of market growth[2][3][5].
- Availability of Generic Versions: The cost-effectiveness of generic lisinopril has increased patient adherence and expanded market reach[2].
- Innovations in Drug Delivery: The development of precision medicine and combination therapies involving lisinopril is expected to enhance treatment efficacy and patient outcomes[4].
- Aging Population: The growing elderly population, which is more prone to cardiovascular diseases, will further drive the demand for lisinopril[2].
Opportunities and Challenges
Opportunities
- Precision Medicine and Personalised Therapies: Studies like the OptiZest study are paving the way for personalised dose optimisation, which could improve treatment outcomes and patient adherence[4].
- Combination Therapies: The exploration of combination therapies involving lisinopril with other cardiovascular medications could provide synergistic effects and improve overall treatment efficacy[3].
Challenges
- Side Effects and Tolerability Issues: Common side effects such as dizziness, headaches, and cough can affect patient adherence. Addressing these issues through innovative delivery methods and combination therapies is crucial[5].
Key Takeaways
- Clinical Trials: Ongoing studies like the OptiZest study are focusing on personalised dose optimisation to improve blood pressure control.
- Market Size: The global lisinopril market is projected to grow from $1.66 billion in 2023 to $317.15 million by 2031.
- Regional Growth: Asia-Pacific is expected to be the fastest-growing region in the forecast period.
- Market Drivers: Increasing prevalence of hypertension, availability of generic versions, innovations in drug delivery, and an aging population are key drivers.
- Opportunities: Precision medicine, combination therapies, and increased public awareness are significant opportunities for market growth.
FAQs
What is the primary use of Zestril (lisinopril)?
Zestril (lisinopril) is primarily used to treat high blood pressure (hypertension), heart failure, and certain kidney conditions related to diabetes.
What is the OptiZest study about?
The OptiZest study is a clinical trial investigating whether a personalised dose of Zestril (lisinopril) can improve blood pressure control in patients with hypertension using Closed Loop’s proprietary Software-as-a-Medical Device (SaMD) dose optimisation technology.
What are the key drivers of the lisinopril market growth?
The key drivers include the increasing prevalence of hypertension and cardiovascular diseases, the availability of generic versions, innovations in drug delivery, and an aging population.
Which region is expected to be the fastest-growing in the lisinopril market?
The Asia-Pacific region is expected to be the fastest-growing region in the forecast period.
What are some of the common side effects of lisinopril?
Common side effects include dizziness, headaches, and cough.
Sources
- AstraZeneca Full-year-and-Q4-2023-results-clinical-trials-appendix.pdf
- The Business Research Company - Lisinopril Global Market Report 2024
- Data Bridge Market Research - Global Lisinopril Market
- PharmaTimes - Closed Loop and Pharmanovia investigate precision medicine combination in hypertension
- Value Market Research - Global Lisinopril Market Research Report
Last updated: 2025-01-06
